| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community-Acquired Infections | 60 | 2024 | 102 | 13.360 |
Why?
|
| Pneumonia, Pneumococcal | 31 | 2023 | 100 | 9.280 |
Why?
|
| Pneumococcal Infections | 36 | 2023 | 299 | 7.730 |
Why?
|
| Anti-Bacterial Agents | 59 | 2024 | 293 | 7.090 |
Why?
|
| Pneumonia | 29 | 2024 | 131 | 6.830 |
Why?
|
| Streptococcus pneumoniae | 51 | 2023 | 336 | 6.600 |
Why?
|
| Humans | 285 | 2024 | 14537 | 4.750 |
Why?
|
| Streptolysins | 29 | 2024 | 29 | 4.580 |
Why?
|
| Neutrophils | 34 | 2024 | 53 | 3.800 |
Why?
|
| Smoking | 14 | 2024 | 100 | 3.270 |
Why?
|
| Blood Platelets | 7 | 2022 | 30 | 3.050 |
Why?
|
| Pneumonia, Bacterial | 17 | 2020 | 54 | 3.050 |
Why?
|
| Intensive Care Units | 16 | 2024 | 66 | 2.860 |
Why?
|
| Pneumococcal Vaccines | 18 | 2022 | 278 | 2.840 |
Why?
|
| Cardiovascular Diseases | 6 | 2023 | 237 | 2.720 |
Why?
|
| Platelet Activation | 10 | 2022 | 17 | 2.680 |
Why?
|
| Adult | 116 | 2024 | 5913 | 2.230 |
Why?
|
| Macrolides | 13 | 2023 | 15 | 2.130 |
Why?
|
| HIV Infections | 32 | 2024 | 5097 | 2.040 |
Why?
|
| Aged | 55 | 2024 | 1740 | 1.950 |
Why?
|
| Endothelium, Vascular | 8 | 2022 | 29 | 1.930 |
Why?
|
| Bacterial Proteins | 31 | 2024 | 119 | 1.920 |
Why?
|
| Bronchiectasis | 8 | 2021 | 11 | 1.880 |
Why?
|
| Male | 108 | 2024 | 6754 | 1.880 |
Why?
|
| Middle Aged | 82 | 2024 | 3601 | 1.870 |
Why?
|
| Respiratory Tract Infections | 11 | 2024 | 266 | 1.860 |
Why?
|
| Severity of Illness Index | 27 | 2024 | 253 | 1.820 |
Why?
|
| Bacteremia | 11 | 2018 | 79 | 1.810 |
Why?
|
| Drug Resistance, Bacterial | 15 | 2024 | 135 | 1.710 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 10 | 2020 | 37 | 1.630 |
Why?
|
| Quality of Life | 8 | 2024 | 177 | 1.600 |
Why?
|
| Critical Illness | 6 | 2024 | 44 | 1.580 |
Why?
|
| Female | 106 | 2024 | 9103 | 1.530 |
Why?
|
| Withholding Treatment | 5 | 2024 | 26 | 1.520 |
Why?
|
| Risk Factors | 31 | 2024 | 1475 | 1.510 |
Why?
|
| Biofilms | 6 | 2019 | 15 | 1.450 |
Why?
|
| South Africa | 72 | 2024 | 7596 | 1.400 |
Why?
|
| Fluoroquinolones | 5 | 2019 | 20 | 1.400 |
Why?
|
| Inflammation | 15 | 2024 | 104 | 1.340 |
Why?
|
| Coronary Artery Disease | 7 | 2017 | 30 | 1.310 |
Why?
|
| AIDS-Related Opportunistic Infections | 9 | 2024 | 195 | 1.300 |
Why?
|
| Tuberculosis, Pulmonary | 15 | 2017 | 324 | 1.270 |
Why?
|
| Cross Infection | 9 | 2019 | 52 | 1.260 |
Why?
|
| Anti-Inflammatory Agents | 8 | 2013 | 39 | 1.200 |
Why?
|
| Life Support Care | 4 | 2024 | 10 | 1.180 |
Why?
|
| Terminal Care | 4 | 2024 | 35 | 1.150 |
Why?
|
| Asthma | 14 | 2020 | 33 | 1.130 |
Why?
|
| Critical Care | 9 | 2024 | 52 | 1.130 |
Why?
|
| Adrenal Cortex Hormones | 8 | 2023 | 21 | 1.130 |
Why?
|
| Global Health | 3 | 2020 | 193 | 1.100 |
Why?
|
| Calcium | 18 | 2024 | 49 | 1.080 |
Why?
|
| Plaque, Atherosclerotic | 7 | 2017 | 27 | 1.040 |
Why?
|
| Prospective Studies | 32 | 2024 | 1160 | 1.040 |
Why?
|
| Glucocorticoids | 4 | 2023 | 20 | 1.040 |
Why?
|
| Rhinitis, Allergic | 2 | 2023 | 2 | 1.010 |
Why?
|
| Respiration, Artificial | 8 | 2024 | 47 | 1.000 |
Why?
|
| Heart Diseases | 2 | 2016 | 19 | 0.940 |
Why?
|
| Sepsis | 9 | 2024 | 102 | 0.930 |
Why?
|
| Shock, Septic | 2 | 2023 | 10 | 0.930 |
Why?
|
| HIV Seropositivity | 7 | 2013 | 265 | 0.930 |
Why?
|
| Treatment Outcome | 22 | 2018 | 889 | 0.920 |
Why?
|
| Nasal Mucosa | 8 | 2005 | 8 | 0.910 |
Why?
|
| Lung | 9 | 2017 | 70 | 0.900 |
Why?
|
| Mineralocorticoids | 2 | 2023 | 2 | 0.880 |
Why?
|
| Biomarkers | 13 | 2021 | 327 | 0.870 |
Why?
|
| Leukotriene Antagonists | 6 | 2014 | 6 | 0.870 |
Why?
|
| Alcohol Drinking | 1 | 2024 | 55 | 0.870 |
Why?
|
| Guideline Adherence | 6 | 2020 | 43 | 0.850 |
Why?
|
| Sarcoidosis | 4 | 2022 | 8 | 0.850 |
Why?
|
| Aged, 80 and over | 18 | 2020 | 468 | 0.850 |
Why?
|
| Metabolic Syndrome | 1 | 2024 | 64 | 0.850 |
Why?
|
| Bacterial Infections | 8 | 2016 | 54 | 0.840 |
Why?
|
| Hydrocortisone | 4 | 2023 | 10 | 0.820 |
Why?
|
| Coronary Vessels | 7 | 2017 | 12 | 0.800 |
Why?
|
| Drug Therapy, Combination | 15 | 2018 | 279 | 0.800 |
Why?
|
| Neutrophil Activation | 11 | 2024 | 12 | 0.800 |
Why?
|
| Animals | 13 | 2021 | 1081 | 0.790 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2022 | 11 | 0.780 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 146 | 0.780 |
Why?
|
| Practice Guidelines as Topic | 9 | 2020 | 127 | 0.770 |
Why?
|
| Serogroup | 6 | 2022 | 150 | 0.760 |
Why?
|
| Receptors, Leukotriene | 3 | 2014 | 3 | 0.760 |
Why?
|
| Coronary Angiography | 8 | 2017 | 14 | 0.760 |
Why?
|
| Rhinitis | 3 | 2020 | 5 | 0.740 |
Why?
|
| Virulence Factors | 2 | 2020 | 18 | 0.740 |
Why?
|
| Retrospective Studies | 19 | 2024 | 799 | 0.710 |
Why?
|
| Tuberculosis | 3 | 2021 | 543 | 0.690 |
Why?
|
| Stress, Physiological | 4 | 2015 | 5 | 0.680 |
Why?
|
| Anti-Asthmatic Agents | 5 | 2014 | 5 | 0.680 |
Why?
|
| Immunocompromised Host | 3 | 2021 | 34 | 0.670 |
Why?
|
| Integrons | 2 | 2019 | 2 | 0.670 |
Why?
|
| Cilia | 7 | 2006 | 7 | 0.670 |
Why?
|
| Hypoaldosteronism | 1 | 2020 | 1 | 0.670 |
Why?
|
| Plasmids | 2 | 2019 | 23 | 0.670 |
Why?
|
| Genome, Bacterial | 2 | 2019 | 32 | 0.670 |
Why?
|
| Adolescent | 33 | 2020 | 2985 | 0.650 |
Why?
|
| Attitude of Health Personnel | 4 | 2018 | 106 | 0.640 |
Why?
|
| Smoke | 1 | 2019 | 2 | 0.640 |
Why?
|
| Providencia | 1 | 2019 | 1 | 0.630 |
Why?
|
| Replicon | 1 | 2019 | 2 | 0.630 |
Why?
|
| Immunologic Factors | 3 | 2014 | 9 | 0.630 |
Why?
|
| Prostatitis | 1 | 2019 | 2 | 0.620 |
Why?
|
| Typhoid Fever | 1 | 2019 | 2 | 0.620 |
Why?
|
| Prosthesis-Related Infections | 1 | 2019 | 2 | 0.620 |
Why?
|
| Disease Progression | 8 | 2021 | 154 | 0.610 |
Why?
|
| Societies, Medical | 3 | 2024 | 26 | 0.610 |
Why?
|
| Acetates | 5 | 2014 | 7 | 0.600 |
Why?
|
| Quinolines | 5 | 2014 | 14 | 0.590 |
Why?
|
| Clostridium Infections | 1 | 2018 | 1 | 0.590 |
Why?
|
| Vaccines, Conjugate | 6 | 2020 | 171 | 0.590 |
Why?
|
| Lung Diseases | 5 | 2024 | 29 | 0.590 |
Why?
|
| Cyclic AMP | 5 | 2014 | 7 | 0.590 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 253 | 0.570 |
Why?
|
| Primary Health Care | 5 | 2016 | 240 | 0.570 |
Why?
|
| Ceftriaxone | 5 | 2014 | 13 | 0.560 |
Why?
|
| Microbial Sensitivity Tests | 12 | 2019 | 198 | 0.550 |
Why?
|
| Klebsiella Infections | 5 | 2020 | 13 | 0.550 |
Why?
|
| Hospitalization | 11 | 2021 | 418 | 0.550 |
Why?
|
| Catecholamines | 2 | 2014 | 6 | 0.540 |
Why?
|
| Coronary Circulation | 5 | 2017 | 10 | 0.540 |
Why?
|
| Troponin T | 1 | 2017 | 1 | 0.530 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 13 | 2011 | 13 | 0.530 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 7 | 2021 | 10 | 0.530 |
Why?
|
| Ethanolamines | 3 | 2014 | 5 | 0.520 |
Why?
|
| Albuterol | 4 | 2014 | 6 | 0.520 |
Why?
|
| Drug Utilization | 2 | 2016 | 10 | 0.510 |
Why?
|
| Clarithromycin | 5 | 2007 | 5 | 0.510 |
Why?
|
| Enterobacteriaceae Infections | 4 | 2019 | 10 | 0.510 |
Why?
|
| Young Adult | 12 | 2021 | 2498 | 0.510 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2019 | 226 | 0.500 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2012 | 35 | 0.500 |
Why?
|
| C-Reactive Protein | 6 | 2021 | 96 | 0.500 |
Why?
|
| Tertiary Care Centers | 3 | 2024 | 80 | 0.490 |
Why?
|
| Superoxides | 11 | 2010 | 11 | 0.480 |
Why?
|
| Immunity, Mucosal | 1 | 2015 | 2 | 0.480 |
Why?
|
| Phospholipids | 3 | 2001 | 13 | 0.470 |
Why?
|
| DNA-Binding Proteins | 2 | 2017 | 20 | 0.470 |
Why?
|
| Pyrroles | 2 | 2014 | 12 | 0.470 |
Why?
|
| Penicillin Resistance | 6 | 2005 | 17 | 0.470 |
Why?
|
| Decision Making | 4 | 2024 | 53 | 0.460 |
Why?
|
| Acute-Phase Proteins | 1 | 2014 | 14 | 0.450 |
Why?
|
| Virulence | 5 | 2020 | 25 | 0.450 |
Why?
|
| Prognosis | 15 | 2015 | 199 | 0.450 |
Why?
|
| Hospital Mortality | 6 | 2024 | 95 | 0.450 |
Why?
|
| Cytosol | 6 | 2016 | 9 | 0.440 |
Why?
|
| Child | 15 | 2022 | 2242 | 0.440 |
Why?
|
| Morals | 1 | 2014 | 5 | 0.440 |
Why?
|
| Smoking Prevention | 2 | 2013 | 5 | 0.440 |
Why?
|
| Protein Kinases | 1 | 2014 | 4 | 0.440 |
Why?
|
| Smoking Cessation | 2 | 2013 | 9 | 0.440 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2021 | 61 | 0.430 |
Why?
|
| Disease Management | 4 | 2020 | 74 | 0.430 |
Why?
|
| Indans | 1 | 2014 | 1 | 0.430 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2014 | 1 | 0.430 |
Why?
|
| Quinolones | 1 | 2014 | 7 | 0.430 |
Why?
|
| Heptanoic Acids | 1 | 2014 | 10 | 0.430 |
Why?
|
| Membrane Proteins | 1 | 2014 | 36 | 0.430 |
Why?
|
| Shear Strength | 1 | 2013 | 1 | 0.420 |
Why?
|
| Sputum | 8 | 2017 | 135 | 0.420 |
Why?
|
| Respiratory Insufficiency | 8 | 2018 | 17 | 0.420 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 33 | 0.400 |
Why?
|
| Infection Control | 4 | 2017 | 31 | 0.390 |
Why?
|
| Medically Underserved Area | 1 | 2012 | 13 | 0.390 |
Why?
|
| Urban Health Services | 1 | 2012 | 10 | 0.390 |
Why?
|
| Epithelium | 7 | 2006 | 8 | 0.390 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2016 | 5 | 0.380 |
Why?
|
| P-Selectin | 4 | 2021 | 7 | 0.380 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2021 | 472 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2021 | 125 | 0.370 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 43 | 0.370 |
Why?
|
| Anti-Infective Agents | 7 | 2017 | 57 | 0.370 |
Why?
|
| Reactive Oxygen Species | 6 | 2024 | 23 | 0.370 |
Why?
|
| Research Design | 1 | 2012 | 124 | 0.360 |
Why?
|
| Prevalence | 8 | 2023 | 1192 | 0.360 |
Why?
|
| Influenza, Human | 4 | 2021 | 374 | 0.360 |
Why?
|
| Drug Synergism | 3 | 2007 | 20 | 0.360 |
Why?
|
| Pancreatic Elastase | 9 | 2024 | 9 | 0.360 |
Why?
|
| Hydrogen Peroxide | 3 | 2017 | 11 | 0.360 |
Why?
|
| Leukotriene B4 | 6 | 2014 | 6 | 0.350 |
Why?
|
| Risk Assessment | 6 | 2019 | 225 | 0.340 |
Why?
|
| Extracellular Traps | 2 | 2024 | 2 | 0.340 |
Why?
|
| Acute Coronary Syndrome | 3 | 2015 | 13 | 0.340 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 280 | 0.340 |
Why?
|
| Phylogeny | 3 | 2019 | 231 | 0.340 |
Why?
|
| Ultrasonography, Interventional | 4 | 2017 | 10 | 0.340 |
Why?
|
| Immunization | 4 | 2020 | 63 | 0.330 |
Why?
|
| Phosphodiesterase Inhibitors | 3 | 2000 | 10 | 0.330 |
Why?
|
| Stents | 2 | 2016 | 10 | 0.330 |
Why?
|
| Mycobacterium tuberculosis | 10 | 2021 | 329 | 0.330 |
Why?
|
| Alleles | 3 | 2022 | 143 | 0.320 |
Why?
|
| Drug Resistance, Microbial | 6 | 2024 | 26 | 0.320 |
Why?
|
| Immunoglobulin G | 4 | 2022 | 231 | 0.320 |
Why?
|
| Oxidants | 3 | 2004 | 6 | 0.320 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2015 | 151 | 0.310 |
Why?
|
| Ketolides | 2 | 1999 | 2 | 0.310 |
Why?
|
| Klebsiella pneumoniae | 5 | 2020 | 39 | 0.310 |
Why?
|
| Immunity, Innate | 3 | 2014 | 10 | 0.310 |
Why?
|
| Pharmacists | 3 | 2020 | 4 | 0.300 |
Why?
|
| Length of Stay | 7 | 2018 | 43 | 0.300 |
Why?
|
| Amoxicillin | 3 | 2007 | 9 | 0.300 |
Why?
|
| Age Factors | 8 | 2015 | 370 | 0.300 |
Why?
|
| Incidence | 9 | 2017 | 685 | 0.290 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2018 | 262 | 0.290 |
Why?
|
| Chronic Disease | 4 | 2020 | 107 | 0.280 |
Why?
|
| Imipenem | 3 | 2012 | 6 | 0.280 |
Why?
|
| Cells, Cultured | 10 | 2024 | 79 | 0.280 |
Why?
|
| Child, Preschool | 9 | 2022 | 1748 | 0.270 |
Why?
|
| Multiple Organ Failure | 2 | 2018 | 4 | 0.270 |
Why?
|
| Vaccination | 5 | 2020 | 365 | 0.270 |
Why?
|
| Minocycline | 3 | 2012 | 3 | 0.270 |
Why?
|
| United States | 7 | 2024 | 132 | 0.270 |
Why?
|
| Rhinitis, Allergic, Seasonal | 2 | 2020 | 2 | 0.270 |
Why?
|
| Rhinitis, Allergic, Perennial | 2 | 2020 | 2 | 0.270 |
Why?
|
| Acute Disease | 9 | 2016 | 105 | 0.260 |
Why?
|
| alpha 1-Antitrypsin | 4 | 2004 | 6 | 0.260 |
Why?
|
| Adenosine Diphosphate | 3 | 2022 | 4 | 0.260 |
Why?
|
| Platelet Activating Factor | 4 | 2016 | 5 | 0.250 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2017 | 12 | 0.250 |
Why?
|
| Mucociliary Clearance | 4 | 2001 | 4 | 0.250 |
Why?
|
| Gene Frequency | 3 | 2022 | 122 | 0.250 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2006 | 1 | 0.250 |
Why?
|
| Lung Diseases, Obstructive | 3 | 1996 | 5 | 0.250 |
Why?
|
| Predictive Value of Tests | 7 | 2017 | 188 | 0.250 |
Why?
|
| Sulfides | 5 | 2014 | 5 | 0.250 |
Why?
|
| Anti-Retroviral Agents | 4 | 2018 | 551 | 0.250 |
Why?
|
| Bronchiolitis, Viral | 2 | 2016 | 9 | 0.240 |
Why?
|
| Patient Education as Topic | 5 | 2020 | 48 | 0.240 |
Why?
|
| Azithromycin | 3 | 2007 | 3 | 0.240 |
Why?
|
| Coronary Restenosis | 2 | 2016 | 4 | 0.240 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 3 | 2012 | 33 | 0.240 |
Why?
|
| Cyclopropanes | 5 | 2014 | 123 | 0.240 |
Why?
|
| Case-Control Studies | 7 | 2014 | 480 | 0.240 |
Why?
|
| HIV | 3 | 2021 | 380 | 0.230 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 58 | 0.230 |
Why?
|
| Platinum Compounds | 1 | 2005 | 1 | 0.230 |
Why?
|
| Long-Term Care | 3 | 2018 | 13 | 0.230 |
Why?
|
| Pneumonia, Viral | 2 | 2021 | 104 | 0.230 |
Why?
|
| Calcitonin | 1 | 2005 | 10 | 0.230 |
Why?
|
| Tomography, Optical Coherence | 2 | 2015 | 3 | 0.230 |
Why?
|
| Protein Precursors | 1 | 2005 | 22 | 0.230 |
Why?
|
| Streptococcus pyogenes | 2 | 2024 | 5 | 0.230 |
Why?
|
| Monocytes | 2 | 2015 | 27 | 0.230 |
Why?
|
| Diabetes Complications | 1 | 2024 | 15 | 0.220 |
Why?
|
| Cohort Studies | 7 | 2021 | 967 | 0.220 |
Why?
|
| Naphthyridines | 1 | 2004 | 1 | 0.220 |
Why?
|
| Clavulanic Acid | 1 | 2004 | 1 | 0.220 |
Why?
|
| Host-Pathogen Interactions | 2 | 2021 | 24 | 0.220 |
Why?
|
| Communicable Disease Control | 2 | 2021 | 101 | 0.220 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 32 | 0.220 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 101 | 0.220 |
Why?
|
| beta-Lactams | 3 | 2017 | 7 | 0.220 |
Why?
|
| Cephalosporin Resistance | 2 | 2005 | 2 | 0.210 |
Why?
|
| Survival Rate | 3 | 2018 | 96 | 0.210 |
Why?
|
| Coinfection | 2 | 2024 | 276 | 0.210 |
Why?
|
| Enterobacteriaceae | 3 | 2012 | 11 | 0.210 |
Why?
|
| Fludrocortisone | 1 | 2023 | 1 | 0.210 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2023 | 3 | 0.210 |
Why?
|
| Histamine Antagonists | 1 | 2023 | 1 | 0.210 |
Why?
|
| APACHE | 5 | 2011 | 12 | 0.210 |
Why?
|
| Carbapenems | 4 | 2019 | 17 | 0.210 |
Why?
|
| Allergens | 1 | 2023 | 4 | 0.210 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 112 | 0.210 |
Why?
|
| Penicillins | 4 | 2014 | 25 | 0.210 |
Why?
|
| Antibodies, Bacterial | 7 | 2007 | 153 | 0.200 |
Why?
|
| Echinococcosis, Pulmonary | 1 | 2003 | 2 | 0.200 |
Why?
|
| Echinococcus | 1 | 2003 | 5 | 0.200 |
Why?
|
| Population Surveillance | 5 | 2015 | 325 | 0.200 |
Why?
|
| Surveys and Questionnaires | 6 | 2016 | 563 | 0.200 |
Why?
|
| HLA-DR Antigens | 1 | 2022 | 13 | 0.200 |
Why?
|
| Theophylline | 3 | 2000 | 5 | 0.200 |
Why?
|
| HLA-DQ Antigens | 1 | 2022 | 8 | 0.200 |
Why?
|
| In Vitro Techniques | 7 | 2016 | 54 | 0.200 |
Why?
|
| Antitubercular Agents | 3 | 2021 | 322 | 0.200 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2022 | 33 | 0.190 |
Why?
|
| Congresses as Topic | 4 | 2014 | 20 | 0.190 |
Why?
|
| Dexamethasone | 1 | 2022 | 13 | 0.190 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 5 | 0.190 |
Why?
|
| Thienamycins | 2 | 2004 | 6 | 0.190 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 2 | 2013 | 4 | 0.190 |
Why?
|
| Pyrrolidinones | 2 | 2021 | 6 | 0.190 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2013 | 656 | 0.190 |
Why?
|
| Escherichia coli | 3 | 2019 | 30 | 0.190 |
Why?
|
| Genomics | 2 | 2019 | 109 | 0.190 |
Why?
|
| Phosphoproteins | 1 | 2022 | 10 | 0.190 |
Why?
|
| Expert Testimony | 1 | 2022 | 2 | 0.190 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2017 | 19 | 0.190 |
Why?
|
| Endothelial Cells | 1 | 2022 | 14 | 0.190 |
Why?
|
| Bucladesine | 2 | 2000 | 2 | 0.190 |
Why?
|
| Myocardium | 1 | 2022 | 35 | 0.180 |
Why?
|
| Anti-HIV Agents | 5 | 2019 | 1324 | 0.180 |
Why?
|
| Aldosterone | 2 | 2020 | 12 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 176 | 0.180 |
Why?
|
| Oximetry | 1 | 2021 | 6 | 0.180 |
Why?
|
| Vitamin E | 1 | 2001 | 9 | 0.180 |
Why?
|
| Common Cold | 2 | 2020 | 3 | 0.180 |
Why?
|
| Indoles | 3 | 2016 | 5 | 0.180 |
Why?
|
| Stress, Mechanical | 5 | 2017 | 16 | 0.180 |
Why?
|
| Kenya | 1 | 2022 | 183 | 0.180 |
Why?
|
| Cell Membrane | 3 | 1999 | 10 | 0.180 |
Why?
|
| Kidney | 3 | 2019 | 46 | 0.180 |
Why?
|
| Platelet Aggregation | 2 | 2021 | 12 | 0.180 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 2000 | 16 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2013 | 150 | 0.180 |
Why?
|
| Masks | 1 | 2021 | 4 | 0.180 |
Why?
|
| Fura-2 | 5 | 2012 | 5 | 0.170 |
Why?
|
| CD40 Ligand | 1 | 2021 | 4 | 0.170 |
Why?
|
| Urinary Tract Infections | 2 | 2019 | 12 | 0.170 |
Why?
|
| Roxithromycin | 2 | 1997 | 2 | 0.170 |
Why?
|
| Chemotactic Factors | 3 | 2009 | 6 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2000 | 17 | 0.170 |
Why?
|
| Picornaviridae Infections | 1 | 2021 | 18 | 0.170 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2011 | 9 | 0.170 |
Why?
|
| Respiration Disorders | 2 | 2009 | 3 | 0.170 |
Why?
|
| Cell Survival | 3 | 2017 | 48 | 0.170 |
Why?
|
| HMGB1 Protein | 1 | 2020 | 1 | 0.170 |
Why?
|
| Thoracic Diseases | 1 | 2020 | 1 | 0.170 |
Why?
|
| Antimicrobial Stewardship | 1 | 2020 | 14 | 0.170 |
Why?
|
| Diarylquinolines | 1 | 2021 | 39 | 0.170 |
Why?
|
| Recombinant Proteins | 9 | 2017 | 73 | 0.170 |
Why?
|
| NF-kappa B | 2 | 2014 | 16 | 0.170 |
Why?
|
| Vaping | 1 | 2020 | 2 | 0.170 |
Why?
|
| Patient Care Management | 1 | 2020 | 9 | 0.170 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2012 | 7 | 0.170 |
Why?
|
| Health Behavior | 1 | 2021 | 79 | 0.160 |
Why?
|
| Bacterial Capsules | 1 | 2020 | 33 | 0.160 |
Why?
|
| Consensus | 4 | 2021 | 62 | 0.160 |
Why?
|
| Morganella morganii | 1 | 2019 | 1 | 0.160 |
Why?
|
| Escherichia coli Proteins | 1 | 2019 | 2 | 0.160 |
Why?
|
| Escherichia coli Infections | 1 | 2019 | 3 | 0.160 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 1999 | 2 | 0.160 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 34 | 0.160 |
Why?
|
| Interspersed Repetitive Sequences | 1 | 2019 | 2 | 0.160 |
Why?
|
| Gram-Negative Bacteria | 3 | 2012 | 15 | 0.160 |
Why?
|
| Intubation, Intratracheal | 2 | 1999 | 9 | 0.160 |
Why?
|
| Respiratory System | 2 | 1997 | 9 | 0.160 |
Why?
|
| Aneurysm, Dissecting | 1 | 2019 | 1 | 0.160 |
Why?
|
| Joint Prosthesis | 1 | 2019 | 1 | 0.160 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2019 | 1 | 0.160 |
Why?
|
| Rupture | 1 | 2019 | 3 | 0.160 |
Why?
|
| Hallucinations | 1 | 2019 | 2 | 0.160 |
Why?
|
| Dopamine | 2 | 2017 | 7 | 0.160 |
Why?
|
| Epinephrine | 2 | 2017 | 9 | 0.150 |
Why?
|
| Norepinephrine | 2 | 2017 | 13 | 0.150 |
Why?
|
| Syndrome | 1 | 2019 | 19 | 0.150 |
Why?
|
| Tendinopathy | 1 | 2019 | 3 | 0.150 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 7 | 0.150 |
Why?
|
| Fluorescent Dyes | 4 | 2012 | 13 | 0.150 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 11 | 0.150 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2011 | 54 | 0.150 |
Why?
|
| Hospitals | 2 | 2017 | 103 | 0.150 |
Why?
|
| Cost of Illness | 2 | 2013 | 167 | 0.150 |
Why?
|
| HIV Seronegativity | 1 | 1999 | 52 | 0.150 |
Why?
|
| Cilastatin | 3 | 2012 | 4 | 0.150 |
Why?
|
| Bronchitis | 1 | 2018 | 2 | 0.150 |
Why?
|
| Carbazoles | 1 | 1998 | 5 | 0.150 |
Why?
|
| Bronchiolitis | 1 | 2018 | 8 | 0.150 |
Why?
|
| Anxiety | 1 | 2019 | 40 | 0.150 |
Why?
|
| Skilled Nursing Facilities | 1 | 2018 | 1 | 0.150 |
Why?
|
| Total Quality Management | 1 | 2018 | 2 | 0.150 |
Why?
|
| Nutrition Therapy | 1 | 2018 | 4 | 0.150 |
Why?
|
| Statistics as Topic | 3 | 2015 | 31 | 0.150 |
Why?
|
| Tobacco | 1 | 2018 | 14 | 0.150 |
Why?
|
| Bone and Bones | 1 | 2019 | 38 | 0.150 |
Why?
|
| Registries | 3 | 2015 | 91 | 0.150 |
Why?
|
| Stavudine | 1 | 2019 | 78 | 0.140 |
Why?
|
| Bronchial Diseases | 2 | 1996 | 2 | 0.140 |
Why?
|
| Malnutrition | 1 | 2018 | 56 | 0.140 |
Why?
|
| Models, Cardiovascular | 2 | 2015 | 2 | 0.140 |
Why?
|
| Haemophilus influenzae | 3 | 2002 | 42 | 0.140 |
Why?
|
| Tenofovir | 1 | 2019 | 171 | 0.140 |
Why?
|
| Epithelial Cells | 1 | 1997 | 14 | 0.140 |
Why?
|
| Adhesins, Bacterial | 1 | 2017 | 12 | 0.140 |
Why?
|
| Genes | 1 | 1997 | 1 | 0.140 |
Why?
|
| Formoterol Fumarate | 3 | 2014 | 3 | 0.140 |
Why?
|
| Proteoglycans | 1 | 2017 | 1 | 0.140 |
Why?
|
| beta-Lactamases | 2 | 2019 | 23 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 9 | 0.140 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2017 | 12 | 0.140 |
Why?
|
| Catheter-Related Infections | 1 | 2017 | 1 | 0.140 |
Why?
|
| Cough | 1 | 2017 | 14 | 0.140 |
Why?
|
| Time Factors | 7 | 2017 | 507 | 0.130 |
Why?
|
| Catheterization, Central Venous | 1 | 2017 | 2 | 0.130 |
Why?
|
| Ascorbic Acid | 1 | 2017 | 13 | 0.130 |
Why?
|
| Patient Care Bundles | 1 | 2017 | 6 | 0.130 |
Why?
|
| Ferritins | 1 | 2017 | 23 | 0.130 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 40 | 0.130 |
Why?
|
| Lactones | 1 | 2017 | 2 | 0.130 |
Why?
|
| Cell Aggregation | 1 | 2017 | 2 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 19 | 0.130 |
Why?
|
| Pyridines | 1 | 2017 | 11 | 0.130 |
Why?
|
| Infant | 8 | 2016 | 2244 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 21 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 385 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2017 | 43 | 0.130 |
Why?
|
| Mice | 1 | 2017 | 135 | 0.130 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2016 | 20 | 0.130 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2016 | 25 | 0.130 |
Why?
|
| Drug Resistance, Multiple | 2 | 2020 | 6 | 0.130 |
Why?
|
| Drug-Eluting Stents | 1 | 2016 | 3 | 0.130 |
Why?
|
| Inflammation Mediators | 2 | 2013 | 22 | 0.130 |
Why?
|
| Bronchodilator Agents | 3 | 2011 | 7 | 0.130 |
Why?
|
| Regression Analysis | 4 | 2015 | 133 | 0.120 |
Why?
|
| Catalase | 3 | 2005 | 3 | 0.120 |
Why?
|
| Superoxide Dismutase | 3 | 2005 | 6 | 0.120 |
Why?
|
| Hospitals, Teaching | 1 | 2016 | 21 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 18 | 0.120 |
Why?
|
| Antiviral Agents | 3 | 2016 | 111 | 0.120 |
Why?
|
| Cryptococcosis | 1 | 1996 | 17 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 3 | 2020 | 260 | 0.120 |
Why?
|
| Penicillin G | 1 | 1996 | 1 | 0.120 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2016 | 200 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 198 | 0.120 |
Why?
|
| DNA | 1 | 2016 | 73 | 0.120 |
Why?
|
| Physicians | 1 | 2016 | 31 | 0.120 |
Why?
|
| Pre-Exposure Prophylaxis | 2 | 2016 | 196 | 0.120 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 1 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2015 | 4 | 0.120 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2015 | 13 | 0.120 |
Why?
|
| Disease Susceptibility | 2 | 2013 | 46 | 0.120 |
Why?
|
| Meningitis, Pneumococcal | 2 | 2014 | 20 | 0.120 |
Why?
|
| Pilot Projects | 4 | 2017 | 179 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2008 | 370 | 0.120 |
Why?
|
| Lysophosphatidylcholines | 3 | 2001 | 3 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2015 | 24 | 0.120 |
Why?
|
| Oxygen Consumption | 2 | 2014 | 15 | 0.120 |
Why?
|
| Logistic Models | 4 | 2017 | 254 | 0.110 |
Why?
|
| Heart Failure | 1 | 2015 | 38 | 0.110 |
Why?
|
| Docosahexaenoic Acids | 2 | 2005 | 3 | 0.110 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 63 | 0.110 |
Why?
|
| Hemodynamics | 1 | 2015 | 32 | 0.110 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 171 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 77 | 0.110 |
Why?
|
| Bioethical Issues | 1 | 2014 | 4 | 0.110 |
Why?
|
| Histidine Kinase | 1 | 2014 | 1 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2014 | 56 | 0.110 |
Why?
|
| Vaccines, Synthetic | 1 | 2014 | 12 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 8 | 0.110 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2014 | 9 | 0.110 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2014 | 1 | 0.110 |
Why?
|
| Chromones | 1 | 2014 | 1 | 0.110 |
Why?
|
| Tosyl Compounds | 1 | 2014 | 1 | 0.110 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2014 | 1 | 0.110 |
Why?
|
| Phenylcarbamates | 1 | 2014 | 8 | 0.110 |
Why?
|
| Brachytherapy | 1 | 1994 | 13 | 0.110 |
Why?
|
| Antigens, Bacterial | 1 | 2014 | 32 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2014 | 10 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1994 | 8 | 0.110 |
Why?
|
| Double-Blind Method | 3 | 2019 | 272 | 0.110 |
Why?
|
| Caspase 12 | 1 | 2014 | 1 | 0.110 |
Why?
|
| Erythromycin | 3 | 2007 | 12 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1994 | 32 | 0.110 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2013 | 5 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2014 | 67 | 0.110 |
Why?
|
| Luminescent Measurements | 3 | 2005 | 4 | 0.100 |
Why?
|
| Swine | 1 | 2013 | 49 | 0.100 |
Why?
|
| Klebsiella | 1 | 1993 | 6 | 0.100 |
Why?
|
| Arab World | 1 | 2013 | 1 | 0.100 |
Why?
|
| Middle East | 1 | 2013 | 8 | 0.100 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2015 | 155 | 0.100 |
Why?
|
| HIV-1 | 1 | 2021 | 1260 | 0.100 |
Why?
|
| Ciliary Motility Disorders | 2 | 2020 | 2 | 0.100 |
Why?
|
| Antioxidants | 1 | 2013 | 26 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 244 | 0.100 |
Why?
|
| Matrix Metalloproteinase 8 | 2 | 2009 | 2 | 0.100 |
Why?
|
| Interleukin-8 | 3 | 2018 | 21 | 0.100 |
Why?
|
| Gastrointestinal Tract | 1 | 2012 | 4 | 0.100 |
Why?
|
| Ultrasonography | 3 | 2016 | 77 | 0.100 |
Why?
|
| Interleukin-6 | 3 | 2018 | 51 | 0.100 |
Why?
|
| Colistin | 1 | 2012 | 5 | 0.100 |
Why?
|
| Pamphlets | 1 | 2012 | 1 | 0.100 |
Why?
|
| Patient Navigation | 1 | 2012 | 1 | 0.100 |
Why?
|
| Boston | 1 | 2012 | 2 | 0.100 |
Why?
|
| Telephone | 1 | 2012 | 5 | 0.100 |
Why?
|
| Self-Help Groups | 1 | 2012 | 3 | 0.100 |
Why?
|
| Social Isolation | 1 | 2012 | 5 | 0.100 |
Why?
|
| Peer Group | 1 | 2012 | 14 | 0.100 |
Why?
|
| Community-Institutional Relations | 1 | 2012 | 6 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2011 | 187 | 0.100 |
Why?
|
| Emotions | 1 | 2012 | 18 | 0.100 |
Why?
|
| Rolipram | 3 | 2010 | 4 | 0.100 |
Why?
|
| Patient Selection | 2 | 2020 | 40 | 0.100 |
Why?
|
| Drug Administration Schedule | 2 | 2004 | 156 | 0.100 |
Why?
|
| Phagocytes | 1 | 2012 | 1 | 0.100 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 4 | 0.100 |
Why?
|
| Patient Preference | 1 | 2012 | 30 | 0.100 |
Why?
|
| Haemophilus | 1 | 1992 | 1 | 0.100 |
Why?
|
| Algorithms | 4 | 2016 | 106 | 0.090 |
Why?
|
| Community Health Services | 1 | 2012 | 58 | 0.090 |
Why?
|
| beta-Lactam Resistance | 1 | 2012 | 5 | 0.090 |
Why?
|
| Cause of Death | 3 | 2017 | 221 | 0.090 |
Why?
|
| Physicians, Family | 1 | 2012 | 4 | 0.090 |
Why?
|
| Physicians, Primary Care | 1 | 2012 | 4 | 0.090 |
Why?
|
| General Practitioners | 1 | 2012 | 7 | 0.090 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2022 | 2 | 0.090 |
Why?
|
| Thrombin | 2 | 2022 | 8 | 0.090 |
Why?
|
| Intraabdominal Infections | 1 | 2012 | 2 | 0.090 |
Why?
|
| Expectorants | 1 | 2011 | 1 | 0.090 |
Why?
|
| Respiratory Therapy | 1 | 2011 | 1 | 0.090 |
Why?
|
| Mental Health | 1 | 2012 | 91 | 0.090 |
Why?
|
| Genotype | 4 | 2020 | 442 | 0.090 |
Why?
|
| Counseling | 1 | 2012 | 143 | 0.090 |
Why?
|
| Focus Groups | 1 | 2012 | 196 | 0.090 |
Why?
|
| Receptors, Immunologic | 1 | 2011 | 5 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 11 | 0.090 |
Why?
|
| Streptococcal Infections | 3 | 2024 | 184 | 0.090 |
Why?
|
| Hemolysin Proteins | 1 | 1990 | 1 | 0.090 |
Why?
|
| Nasal Decongestants | 2 | 2020 | 2 | 0.080 |
Why?
|
| Qualitative Research | 1 | 2012 | 321 | 0.080 |
Why?
|
| Ionophores | 2 | 2022 | 3 | 0.080 |
Why?
|
| Pneumothorax | 3 | 1987 | 4 | 0.080 |
Why?
|
| Pulmonary Fibrosis | 2 | 1990 | 9 | 0.080 |
Why?
|
| Blood Flow Velocity | 2 | 2015 | 17 | 0.080 |
Why?
|
| Hormones | 1 | 1989 | 9 | 0.080 |
Why?
|
| Phenazines | 2 | 2000 | 3 | 0.080 |
Why?
|
| Cytokines | 3 | 2021 | 107 | 0.080 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2000 | 7 | 0.080 |
Why?
|
| Europe | 3 | 2017 | 56 | 0.080 |
Why?
|
| Health Promotion | 1 | 2011 | 109 | 0.080 |
Why?
|
| Leukotriene C4 | 1 | 2009 | 1 | 0.080 |
Why?
|
| Leukotriene D4 | 1 | 2009 | 1 | 0.080 |
Why?
|
| Nursing Homes | 2 | 2018 | 3 | 0.080 |
Why?
|
| Adrenergic beta-Agonists | 3 | 2000 | 25 | 0.080 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2008 | 3 | 0.080 |
Why?
|
| Radiography | 4 | 1998 | 80 | 0.070 |
Why?
|
| Morbidity | 2 | 2015 | 37 | 0.070 |
Why?
|
| Spirometry | 3 | 2011 | 12 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2009 | 151 | 0.070 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1999 | 7 | 0.070 |
Why?
|
| Rats | 3 | 2001 | 130 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2012 | 42 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2011 | 149 | 0.070 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2008 | 31 | 0.070 |
Why?
|
| Health Policy | 1 | 2009 | 140 | 0.070 |
Why?
|
| Influenza B virus | 1 | 2008 | 42 | 0.070 |
Why?
|
| Rifampin | 2 | 2006 | 197 | 0.070 |
Why?
|
| Tobramycin | 1 | 2007 | 1 | 0.070 |
Why?
|
| Doxycycline | 1 | 2007 | 3 | 0.070 |
Why?
|
| Quality Improvement | 2 | 2018 | 34 | 0.070 |
Why?
|
| Cystic Fibrosis | 2 | 2020 | 9 | 0.070 |
Why?
|
| Causality | 2 | 2001 | 7 | 0.070 |
Why?
|
| Cell Degranulation | 2 | 2024 | 7 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 411 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 106 | 0.060 |
Why?
|
| Amphotericin B | 3 | 1996 | 10 | 0.060 |
Why?
|
| Pericarditis | 1 | 2006 | 4 | 0.060 |
Why?
|
| Endocarditis, Bacterial | 1 | 2006 | 7 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2006 | 11 | 0.060 |
Why?
|
| Lung Diseases, Parasitic | 1 | 1986 | 1 | 0.060 |
Why?
|
| Schistosomiasis haematobia | 1 | 1986 | 1 | 0.060 |
Why?
|
| Asthma, Exercise-Induced | 1 | 2006 | 1 | 0.060 |
Why?
|
| Influenza Vaccines | 1 | 2008 | 144 | 0.060 |
Why?
|
| Adrenal Cortex | 1 | 2006 | 2 | 0.060 |
Why?
|
| Calcium Channels | 2 | 2010 | 6 | 0.060 |
Why?
|
| Palivizumab | 2 | 2016 | 10 | 0.060 |
Why?
|
| Japan | 2 | 2016 | 7 | 0.060 |
Why?
|
| Elastic Tissue | 1 | 2005 | 1 | 0.060 |
Why?
|
| Inpatients | 1 | 2006 | 30 | 0.060 |
Why?
|
| Aminoglycosides | 2 | 1996 | 5 | 0.060 |
Why?
|
| Linear Models | 1 | 2005 | 83 | 0.060 |
Why?
|
| Haemophilus Infections | 2 | 1998 | 23 | 0.060 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2006 | 47 | 0.060 |
Why?
|
| Bronchi | 4 | 1991 | 5 | 0.060 |
Why?
|
| Acridines | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cefotaxime | 1 | 2005 | 1 | 0.060 |
Why?
|
| Peptide Synthases | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cysteine | 1 | 2005 | 3 | 0.060 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2005 | 8 | 0.060 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2005 | 7 | 0.060 |
Why?
|
| Dinoprostone | 2 | 2004 | 6 | 0.060 |
Why?
|
| Spectrometry, Fluorescence | 3 | 2012 | 6 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2022 | 1479 | 0.060 |
Why?
|
| Protease Inhibitors | 2 | 2004 | 23 | 0.060 |
Why?
|
| Regional Blood Flow | 2 | 2015 | 8 | 0.060 |
Why?
|
| Models, Biological | 1 | 2005 | 77 | 0.060 |
Why?
|
| Trypsin Inhibitors | 1 | 2004 | 1 | 0.060 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2004 | 2 | 0.060 |
Why?
|
| Palladium | 1 | 2004 | 2 | 0.050 |
Why?
|
| Platinum | 1 | 2004 | 5 | 0.050 |
Why?
|
| Drug Interactions | 2 | 2010 | 31 | 0.050 |
Why?
|
| IgG Deficiency | 2 | 1996 | 2 | 0.050 |
Why?
|
| Pulmonary Medicine | 2 | 2017 | 2 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2024 | 49 | 0.050 |
Why?
|
| Bronchoscopy | 6 | 1996 | 6 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2003 | 13 | 0.050 |
Why?
|
| Vascular Patency | 1 | 2003 | 2 | 0.050 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2003 | 8 | 0.050 |
Why?
|
| Sex Factors | 1 | 2004 | 227 | 0.050 |
Why?
|
| ROC Curve | 2 | 2015 | 51 | 0.050 |
Why?
|
| Respiratory Mucosa | 1 | 2003 | 1 | 0.050 |
Why?
|
| Mycobacterium avium Complex | 1 | 2003 | 2 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2003 | 101 | 0.050 |
Why?
|
| Mycolic Acids | 1 | 2002 | 1 | 0.050 |
Why?
|
| Biopsy | 5 | 1991 | 38 | 0.050 |
Why?
|
| Cell Membrane Permeability | 1 | 2002 | 1 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2002 | 24 | 0.050 |
Why?
|
| Drug Design | 1 | 2002 | 29 | 0.050 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 13 | 0.050 |
Why?
|
| Pheochromocytoma | 1 | 1982 | 1 | 0.050 |
Why?
|
| Pulmonary Edema | 1 | 1982 | 2 | 0.050 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2022 | 85 | 0.050 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1982 | 2 | 0.050 |
Why?
|
| Serotyping | 2 | 2015 | 66 | 0.050 |
Why?
|
| Colombia | 1 | 2021 | 2 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2001 | 27 | 0.050 |
Why?
|
| Fluid Therapy | 1 | 2001 | 25 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 3 | 2003 | 34 | 0.050 |
Why?
|
| Organ Culture Techniques | 2 | 1992 | 6 | 0.050 |
Why?
|
| Lactams | 2 | 2004 | 3 | 0.040 |
Why?
|
| Asia | 2 | 2017 | 72 | 0.040 |
Why?
|
| Death | 1 | 2021 | 14 | 0.040 |
Why?
|
| Research Report | 1 | 2021 | 11 | 0.040 |
Why?
|
| Age Distribution | 1 | 2001 | 107 | 0.040 |
Why?
|
| Estrenes | 1 | 2021 | 1 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2021 | 1 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 2 | 0.040 |
Why?
|
| Long QT Syndrome | 1 | 2021 | 2 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2021 | 6 | 0.040 |
Why?
|
| Platelet-Rich Plasma | 1 | 2021 | 2 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2001 | 63 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2021 | 10 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2001 | 23 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2001 | 32 | 0.040 |
Why?
|
| Hand Disinfection | 1 | 2021 | 9 | 0.040 |
Why?
|
| Fever | 1 | 2001 | 26 | 0.040 |
Why?
|
| Sentinel Surveillance | 1 | 2002 | 115 | 0.040 |
Why?
|
| Comorbidity | 1 | 2001 | 188 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2001 | 18 | 0.040 |
Why?
|
| Rhinovirus | 1 | 2021 | 23 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2011 | 64 | 0.040 |
Why?
|
| Hospitals, Private | 1 | 2020 | 8 | 0.040 |
Why?
|
| Adenosine Triphosphate | 4 | 2004 | 8 | 0.040 |
Why?
|
| Spiramycin | 1 | 2000 | 1 | 0.040 |
Why?
|
| Erythrocyte Membrane | 1 | 2000 | 2 | 0.040 |
Why?
|
| Internationality | 1 | 2020 | 36 | 0.040 |
Why?
|
| Hospitals, Urban | 2 | 1991 | 23 | 0.040 |
Why?
|
| Hospitals, Public | 1 | 2020 | 45 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 284 | 0.040 |
Why?
|
| Peroxidase | 2 | 2016 | 2 | 0.040 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1997 | 22 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2002 | 44 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2000 | 42 | 0.040 |
Why?
|
| Phenethylamines | 1 | 2000 | 2 | 0.040 |
Why?
|
| Adenosine | 1 | 2000 | 6 | 0.040 |
Why?
|
| Genes, Bacterial | 1 | 2020 | 23 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2020 | 47 | 0.040 |
Why?
|
| Genomic Islands | 1 | 2019 | 1 | 0.040 |
Why?
|
| Amikacin | 1 | 2019 | 7 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 60 | 0.040 |
Why?
|
| Cytoplasmic Granules | 1 | 1999 | 1 | 0.040 |
Why?
|
| Pigments, Biological | 1 | 1999 | 2 | 0.040 |
Why?
|
| Homes for the Aged | 1 | 1999 | 2 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2000 | 64 | 0.040 |
Why?
|
| Phenotype | 2 | 1997 | 158 | 0.040 |
Why?
|
| Dyspnea | 2 | 2017 | 10 | 0.040 |
Why?
|
| Gram-Positive Bacteria | 1 | 1999 | 9 | 0.040 |
Why?
|
| Equipment Contamination | 1 | 1999 | 5 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 1999 | 14 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2019 | 7 | 0.040 |
Why?
|
| Alkaloids | 1 | 1998 | 3 | 0.040 |
Why?
|
| Food Quality | 1 | 2018 | 1 | 0.040 |
Why?
|
| Tuberculosis, Miliary | 1 | 1998 | 2 | 0.040 |
Why?
|
| Tuberculosis, Splenic | 1 | 1998 | 2 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 1998 | 19 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 22 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 1998 | 9 | 0.040 |
Why?
|
| Ethics, Medical | 2 | 2014 | 11 | 0.040 |
Why?
|
| Calcium Radioisotopes | 1 | 1998 | 1 | 0.040 |
Why?
|
| Urban Population | 2 | 1992 | 257 | 0.040 |
Why?
|
| Uganda | 1 | 2019 | 197 | 0.040 |
Why?
|
| Metered Dose Inhalers | 2 | 2011 | 3 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2018 | 64 | 0.040 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1997 | 5 | 0.030 |
Why?
|
| Dimethylformamide | 1 | 1997 | 3 | 0.030 |
Why?
|
| Drugs, Investigational | 1 | 1997 | 4 | 0.030 |
Why?
|
| North America | 1 | 2017 | 11 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 22 | 0.030 |
Why?
|
| Leukocytes | 1 | 2017 | 14 | 0.030 |
Why?
|
| Australia | 1 | 2017 | 48 | 0.030 |
Why?
|
| DNA Primers | 2 | 2014 | 55 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2017 | 30 | 0.030 |
Why?
|
| Hypertension | 1 | 1982 | 419 | 0.030 |
Why?
|
| Thromboxane A2 | 1 | 2017 | 2 | 0.030 |
Why?
|
| Hospitals, Rural | 1 | 2017 | 11 | 0.030 |
Why?
|
| Base Sequence | 2 | 2014 | 149 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2017 | 23 | 0.030 |
Why?
|
| Calcimycin | 1 | 1996 | 1 | 0.030 |
Why?
|
| Lung Diseases, Fungal | 2 | 1987 | 3 | 0.030 |
Why?
|
| Zymosan | 1 | 1996 | 2 | 0.030 |
Why?
|
| Respiratory Burst | 1 | 1996 | 2 | 0.030 |
Why?
|
| Mucormycosis | 2 | 1987 | 3 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 1862 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 14 | 0.030 |
Why?
|
| Heart Rate | 1 | 1996 | 32 | 0.030 |
Why?
|
| Neointima | 1 | 2016 | 1 | 0.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2016 | 3 | 0.030 |
Why?
|
| Africa | 2 | 2012 | 376 | 0.030 |
Why?
|
| Metals | 1 | 2016 | 6 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 9 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2016 | 11 | 0.030 |
Why?
|
| Egtazic Acid | 1 | 2016 | 1 | 0.030 |
Why?
|
| Calcium Chelating Agents | 1 | 2016 | 1 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 23 | 0.030 |
Why?
|
| Flucytosine | 1 | 1996 | 4 | 0.030 |
Why?
|
| Referral and Consultation | 2 | 2011 | 57 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 4 | 0.030 |
Why?
|
| Histones | 1 | 2016 | 7 | 0.030 |
Why?
|
| Citrulline | 1 | 2016 | 2 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 6 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 38 | 0.030 |
Why?
|
| Antibody Formation | 1 | 1996 | 61 | 0.030 |
Why?
|
| Thrombosis | 1 | 2016 | 47 | 0.030 |
Why?
|
| Viral Vaccines | 1 | 2016 | 24 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 43 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2016 | 56 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 25 | 0.030 |
Why?
|
| Parents | 1 | 2016 | 32 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 1996 | 40 | 0.030 |
Why?
|
| Family | 1 | 2016 | 35 | 0.030 |
Why?
|
| Hemolysis | 3 | 2005 | 7 | 0.030 |
Why?
|
| Physical Examination | 1 | 2015 | 10 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2016 | 55 | 0.030 |
Why?
|
| Anatomic Landmarks | 1 | 2015 | 2 | 0.030 |
Why?
|
| Communicable Diseases | 1 | 2016 | 62 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 20 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 1992 | 5 | 0.030 |
Why?
|
| World Health Organization | 1 | 2016 | 137 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1995 | 12 | 0.030 |
Why?
|
| Caregivers | 1 | 2016 | 76 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 105 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2015 | 4 | 0.030 |
Why?
|
| Seasons | 1 | 2015 | 154 | 0.030 |
Why?
|
| Cantharidin | 1 | 1994 | 1 | 0.030 |
Why?
|
| Neuromuscular Diseases | 1 | 1994 | 3 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 142 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 1994 | 7 | 0.030 |
Why?
|
| Contraindications | 2 | 2008 | 5 | 0.030 |
Why?
|
| Bacterial Adhesion | 2 | 2006 | 6 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 133 | 0.030 |
Why?
|
| Vascular Calcification | 1 | 2014 | 1 | 0.030 |
Why?
|
| Fibrosis | 1 | 2014 | 11 | 0.030 |
Why?
|
| Advance Directives | 1 | 2014 | 2 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 217 | 0.030 |
Why?
|
| Sodium Hypochlorite | 1 | 1994 | 1 | 0.030 |
Why?
|
| Xanthine Oxidase | 1 | 1994 | 1 | 0.030 |
Why?
|
| Xanthine | 1 | 1994 | 1 | 0.030 |
Why?
|
| Xanthines | 1 | 1994 | 2 | 0.030 |
Why?
|
| Glucose Oxidase | 1 | 1994 | 3 | 0.030 |
Why?
|
| Triage | 1 | 2014 | 11 | 0.030 |
Why?
|
| Ventilator Weaning | 1 | 2014 | 2 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 1994 | 13 | 0.030 |
Why?
|
| Kinetics | 1 | 1994 | 65 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2014 | 52 | 0.030 |
Why?
|
| Culture Media | 2 | 1990 | 15 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2013 | 33 | 0.030 |
Why?
|
| Heart | 1 | 1993 | 27 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2008 | 163 | 0.020 |
Why?
|
| Streptococcus | 1 | 1992 | 2 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 4 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2012 | 19 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2012 | 13 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 1992 | 23 | 0.020 |
Why?
|
| Skin | 1 | 2012 | 38 | 0.020 |
Why?
|
| Leukocyte Elastase | 2 | 2004 | 2 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 74 | 0.020 |
Why?
|
| Europe, Eastern | 1 | 2012 | 3 | 0.020 |
Why?
|
| Latin America | 1 | 2012 | 10 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2012 | 13 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 30 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2012 | 4 | 0.020 |
Why?
|
| Autopsy | 1 | 2012 | 140 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2012 | 29 | 0.020 |
Why?
|
| Dysgammaglobulinemia | 1 | 1992 | 1 | 0.020 |
Why?
|
| Viral Load | 1 | 2016 | 819 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1991 | 1 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 3 | 0.020 |
Why?
|
| Human Experimentation | 1 | 2011 | 2 | 0.020 |
Why?
|
| Toxoids | 1 | 2011 | 1 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 43 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 1991 | 45 | 0.020 |
Why?
|
| Bacteria | 1 | 1992 | 47 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 1991 | 1 | 0.020 |
Why?
|
| Heart-Lung Transplantation | 1 | 1991 | 1 | 0.020 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2011 | 1 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2011 | 1 | 0.020 |
Why?
|
| Forecasting | 1 | 2011 | 20 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 2011 | 10 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1992 | 59 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 1991 | 31 | 0.020 |
Why?
|
| Bartter Syndrome | 1 | 1990 | 1 | 0.020 |
Why?
|
| Cathartics | 1 | 1990 | 1 | 0.020 |
Why?
|
| Edema | 1 | 1990 | 7 | 0.020 |
Why?
|
| Cell Movement | 1 | 1990 | 13 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1990 | 14 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 1990 | 51 | 0.020 |
Why?
|
| Calcium-Transporting ATPases | 2 | 2001 | 2 | 0.020 |
Why?
|
| Cytochalasin B | 1 | 2010 | 1 | 0.020 |
Why?
|
| CD18 Antigens | 1 | 2010 | 1 | 0.020 |
Why?
|
| Life Style | 1 | 2011 | 86 | 0.020 |
Why?
|
| Random Allocation | 2 | 2007 | 23 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 263 | 0.020 |
Why?
|
| Hospitals, General | 1 | 1990 | 1 | 0.020 |
Why?
|
| Electrocardiography | 2 | 1993 | 35 | 0.020 |
Why?
|
| Pharmacopoeias as Topic | 1 | 2009 | 1 | 0.020 |
Why?
|
| Amyloidosis | 1 | 1989 | 3 | 0.020 |
Why?
|
| Mortality | 1 | 1989 | 104 | 0.020 |
Why?
|
| Phospholipases A | 2 | 2001 | 2 | 0.020 |
Why?
|
| Phospholipases A2 | 2 | 2001 | 5 | 0.020 |
Why?
|
| Enterobacter | 1 | 2008 | 2 | 0.020 |
Why?
|
| Exercise | 1 | 2011 | 205 | 0.020 |
Why?
|
| Rimantadine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Amantadine | 1 | 2008 | 6 | 0.020 |
Why?
|
| Embolism, Fat | 1 | 1987 | 1 | 0.020 |
Why?
|
| Femoral Fractures | 1 | 1987 | 1 | 0.020 |
Why?
|
| Tibial Fractures | 1 | 1987 | 1 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2008 | 111 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 1987 | 6 | 0.020 |
Why?
|
| Fibula | 1 | 1987 | 4 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 367 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 1987 | 21 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2008 | 353 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 11 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2008 | 120 | 0.020 |
Why?
|
| Glycopyrrolate | 1 | 1986 | 1 | 0.020 |
Why?
|
| Pulmonary Ventilation | 1 | 1986 | 2 | 0.020 |
Why?
|
| Atropine | 1 | 1986 | 2 | 0.020 |
Why?
|
| Pyrrolidines | 1 | 1986 | 4 | 0.020 |
Why?
|
| Horner Syndrome | 1 | 1986 | 1 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2007 | 127 | 0.020 |
Why?
|
| Foreign Bodies | 1 | 1986 | 2 | 0.020 |
Why?
|
| Suction | 1 | 1986 | 10 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2006 | 1 | 0.020 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2006 | 1 | 0.020 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2006 | 2 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 2006 | 11 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2006 | 26 | 0.020 |
Why?
|
| Immunoassay | 1 | 2006 | 28 | 0.020 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2005 | 1 | 0.010 |
Why?
|
| Transformation, Genetic | 1 | 2005 | 4 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2005 | 53 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 77 | 0.010 |
Why?
|
| Androstadienes | 1 | 2004 | 1 | 0.010 |
Why?
|
| Methionine | 1 | 2004 | 1 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2004 | 3 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2004 | 24 | 0.010 |
Why?
|
| Pharyngitis | 1 | 2004 | 2 | 0.010 |
Why?
|
| Sinusitis | 1 | 2004 | 2 | 0.010 |
Why?
|
| Tonsillitis | 1 | 2004 | 2 | 0.010 |
Why?
|
| Bronchitis, Chronic | 1 | 2004 | 2 | 0.010 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2004 | 2 | 0.010 |
Why?
|
| Cations | 1 | 2004 | 7 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 1989 | 7 | 0.010 |
Why?
|
| Otitis Media | 1 | 2004 | 6 | 0.010 |
Why?
|
| Travel | 1 | 2004 | 21 | 0.010 |
Why?
|
| Myxoma | 1 | 1983 | 3 | 0.010 |
Why?
|
| Heart Neoplasms | 1 | 1983 | 5 | 0.010 |
Why?
|
| Turbinates | 1 | 2003 | 1 | 0.010 |
Why?
|
| Fiber Optic Technology | 3 | 1986 | 3 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 32 | 0.010 |
Why?
|
| Americas | 1 | 2002 | 10 | 0.010 |
Why?
|
| Poisoning | 1 | 1981 | 3 | 0.010 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2001 | 1 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2001 | 1 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 2001 | 2 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2006 | 1422 | 0.010 |
Why?
|
| Potassium | 1 | 2001 | 25 | 0.010 |
Why?
|
| Respiratory Function Tests | 2 | 1991 | 10 | 0.010 |
Why?
|
| Sheep | 1 | 2000 | 9 | 0.010 |
Why?
|
| Cholinergic Antagonists | 1 | 2000 | 5 | 0.010 |
Why?
|
| Homeostasis | 1 | 2000 | 9 | 0.010 |
Why?
|
| Sodium | 1 | 1999 | 30 | 0.010 |
Why?
|
| Bacterial Vaccines | 1 | 1977 | 13 | 0.010 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1977 | 35 | 0.010 |
Why?
|
| Meningococcal Infections | 1 | 1977 | 24 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1996 | 2 | 0.010 |
Why?
|
| Research | 1 | 1997 | 65 | 0.010 |
Why?
|
| Salmeterol Xinafoate | 1 | 1996 | 1 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1996 | 2 | 0.010 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 1996 | 2 | 0.010 |
Why?
|
| Fenoterol | 1 | 1996 | 3 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1996 | 435 | 0.010 |
Why?
|
| Valine | 1 | 1994 | 6 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1994 | 45 | 0.010 |
Why?
|
| Alanine | 1 | 1994 | 31 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 1993 | 2 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1993 | 7 | 0.010 |
Why?
|
| Coma | 1 | 1993 | 1 | 0.010 |
Why?
|
| Emergencies | 1 | 1993 | 16 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1994 | 181 | 0.010 |
Why?
|
| Haplotypes | 1 | 1994 | 125 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1992 | 13 | 0.010 |
Why?
|
| Tuberculin Test | 1 | 1991 | 49 | 0.010 |
Why?
|
| Electrolytes | 1 | 1990 | 5 | 0.010 |
Why?
|
| Autolysis | 1 | 1989 | 1 | 0.000 |
Why?
|
| False Positive Reactions | 1 | 1989 | 17 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 25 | 0.000 |
Why?
|
| Microscopy | 1 | 1989 | 21 | 0.000 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1989 | 7 | 0.000 |
Why?
|
| Medical Records | 1 | 1989 | 23 | 0.000 |
Why?
|
| Cholesterol | 1 | 1989 | 38 | 0.000 |
Why?
|
| Tracheal Diseases | 1 | 1989 | 1 | 0.000 |
Why?
|
| Bacteriological Techniques | 1 | 1989 | 54 | 0.000 |
Why?
|
| Fluoroscopy | 1 | 1987 | 1 | 0.000 |
Why?
|
| Tachycardia, Supraventricular | 1 | 1987 | 1 | 0.000 |
Why?
|
| Hypoxia | 1 | 1987 | 12 | 0.000 |
Why?
|
| Ventilators, Mechanical | 1 | 1987 | 2 | 0.000 |
Why?
|
| Hemorrhage | 1 | 1987 | 72 | 0.000 |
Why?
|
| Rhizopus | 1 | 1986 | 1 | 0.000 |
Why?
|
| Trachea | 1 | 1986 | 3 | 0.000 |
Why?
|
| Heart Atria | 1 | 1983 | 7 | 0.000 |
Why?
|
| Cerebrovascular Disorders | 1 | 1983 | 10 | 0.000 |
Why?
|
| Cardiac Catheterization | 1 | 1983 | 6 | 0.000 |
Why?
|
| Echocardiography | 1 | 1983 | 100 | 0.000 |
Why?
|